Hodgkin lymphoma (HL) is a type of cancer that ... components of treatment for relapsed or refractory HL is stem cell transplantation, particularly autologous hematopoietic cell transplantation ...

Dan Evans, 19, from Newark in Nottinghamshire, described his huge relief ringing the "cancer-free bell" at the teenage cancer ...

The new first-line MCL indication gives Calquence a slice of the market of its own and could spur further growth of the drug, ...

Kinase Inhibitors These drugs block certain enzymes that control cell growth, helping to keep lymphoma cells from growing ... parts of the immune system. Stem cells are removed from the blood ...

The drug received accelerated approval in October 2017 as monotherapy for adults with MCL who have received at least one ...

AstraZeneca’s CALQUENCE® (acalabrutinib) in combination with bendamustine and rituximab has been approved in the US for the treatment of adult patients with previously untreated mantle cell lymphoma ...

Investing.com -- AstraZeneca (LON: AZN) in a stock exchange filing on Friday said that the FDA approved its drug Calquence ...

The Food and Drug Administration has granted traditional approval to Calquence with bendamustine and Rituxan for some ...

The approval of Calquence marks the first and only BTK inhibitor approved for the first-line treatment of MCL in the US.

A donor bone marrow transplant, also called allogeneic hematopoietic stem cell transplantation (alloHSCT), replaces unhealthy stem cells with healthy stem cells and is crucial for treating AML and ...

AstraZeneca (AZN) stock in focus as the U.S. FDA expands approval for its lymphoma therapy Calquence with chemoimmunotherapy ...

Approval follows results from the Phase III ECHO trial, which demonstrated that Calquence plus chemotherapy reduced the risk ...